Skip to content

Peanut Butter and Brain Health

Long-term effects of peanut butter consumption on brain health in middle-aged and older men and women - Peanut Butter and Brain Health

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON58396
Enrollment
45
Registered
2025-09-26
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome, Syndrome X, Insulin Resistance Syndrome Metabolic Syndrome

Interventions

Study participants will receive, in random order, 45 g of peanut butter daily (peanut intervention) or no peanut butter (control) for a total of 16 weeks, separated by a wash-out period of at least 8

Sponsors

Universiteit Maastricht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Men and women, aged between 45-75 years- Women postmenopausal: two or more years after last menstruation- Fasting plasma glucose < 7.0 mmol/L- Fasting serum total cholesterol < 8.0 mmol/L- Fasting serum triacylglycerol < 4.5 mmol/L- Systolic blood pressure < 160 mmHg and diastolic blood pressure < 100 mmHg- Stable body weight (weight gain or loss < 3 kg in the past three months)- Willingness to give up being a blood donor from 8 weeks before the start of the study, during the study and for 4 weeksafter completion of the study- No difficult venipuncture as evidenced during the screening visit

Exclusion criteria

Exclusion criteria: -           Allergy or intolerance to peanuts-           Left-handedness (effects on brain health differ between left- and right-handed adults)-           Current smoker, or smoking cessation < 12 months-           Diabetic patients -           Familial hypercholesterolemia-           Abuse of drugs-           More than 3 alcoholic consumptions per day-           Use of products or dietary supplements known to interfere with the main outcomes as judged by the principal investigators-           Use of medication to treat blood pressure, lipid, or glucose metabolism -           Use of an investigational product within another biomedical intervention trial within the previous 1-month-           Severe medical conditions that might interfere with the study, such as epilepsy, asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease, inflammatory bowel diseases, auto inflammatory diseases, and rheumatoid arthritis-           Active cardiovascular disease like congestive heart failure or cardiovascular event, such as an acute myocardial infarction or cerebrovascular accident-           Contra-indications for MRI imaging (e.g., pacemaker, surgical clips/material in body, metal splinter in eye, claustrophobia)

Design outcomes

Primary

MeasureTime frame
The primary endpoint is the difference at follow-up in the cerebral blood flow response between peanut butter intervention and control periods.

Secondary

MeasureTime frame
Cognitive performance will be assessed, while we will also focus on appetite-related brain reward activity.

Countries

Netherlands

Contacts

Public ContactPJ Joris

Universiteit Maastricht

p.joris@maastrichtuniversity.nl0883887250

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026